Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients. In part 2 of this interview, Joyce Ohm, PhD, explains ...
Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the ...
Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the ...
Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...
Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...
Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...
Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...
FDA accepted an NDA for daraxonrasib in previously treated metastatic PDAC, supported by RASolute 302 and prior breakthrough therapy and orphan drug designations. Phase 3 RASolute 302 showed OS nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results